September 2022

Disparities Among Hispanic Adolescents, Young Adults With Acute ALL

Research has established that there is an increasing recognition that the incidence of acute lymphoblastic leukemia (ALL) among Hispanic individuals living in the United States surpasses the incidence among non-Hispanic populations, especially in adolescents and young adult patients. Learn more about findings recently published and what researchers have to say about inequity in cancer clinical trial enrollment.



FDA Authorizes Novavax COVID-19 Vaccine, Adjuvanted Use in Adolescents
On August 19, 2022, Novavax, Inc., announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) received expanded Emergency Use Authorization from the FDA to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 in adolescents aged 12 through 17 years. Read more.

Phase III Trial of Cannabidiol for Treating EMAS Initiated
Jazz Pharmaceuticals recently announced the initiation of a new phase III trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with epilepsy with myoclonic-atonic seizures (EMAS). The company’s cannabidiol is not currently approved in the United States or European Union for the treatment of EMAS. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App